<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02920801</url>
  </required_header>
  <id_info>
    <org_study_id>13040490434</org_study_id>
    <nct_id>NCT02920801</nct_id>
  </id_info>
  <brief_title>Study About Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Medical Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <brief_summary>
    <textblock>
      In this study, the investigators aim to investigate whether saxagliptin modulate endothelial
      progenitor cells number and flow-mediated dilation in newly diagnosed, treatment-naive type 2
      diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endothelial progenitor cell</measure>
    <time_frame>12weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>flow-mediated dilation</measure>
    <time_frame>12weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>12weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting blood glucose</measure>
    <time_frame>12weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 hour postprandial blood glucose</measure>
    <time_frame>12weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver function test</measure>
    <time_frame>12weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function test</measure>
    <time_frame>12weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>saxagliptin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>saxagliptin group consumed saxagliptin 5mg per day for 12 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metformin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin group consumed metformin 1500mg per day for 12 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saxagliptin</intervention_name>
    <description>5mg per day for 12 weeks</description>
    <arm_group_label>saxagliptin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>1500mg per day for 12 weeks</description>
    <arm_group_label>metformin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed type 2 diabetics (diagnosis were made according to the American
             Diabetes Association Guideline [19] ), treatment naive, age 30-75, hemoglobin A1c
             (HbA1c) â‰¥6.5%, fasting c-peptide &gt;1.0ng/L

        Exclusion Criteria:

          -  pregnancy or lactation, smoker, acute disease or infection, chronic renal disease
             (estimated glomerular filtration rate &lt;60 mL/min/1.73m2), live enzymes 3 times above
             the normal range, positive islet autoantibody, fasting c-peptide &lt;1.0ng/L, severe
             hypertriglyceridemia (triglyceride &gt;5.6mmol/L), cardiovascular events or surgery
             within 3 months, taking glucocorticoid, history of acute or chronic pancreatitis,
             pancreatic tumor, severe cardiac or pneumonic disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fang Li</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2016</study_first_submitted>
  <study_first_submitted_qc>September 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2016</study_first_posted>
  <last_update_submitted>September 30, 2016</last_update_submitted>
  <last_update_submitted_qc>September 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Yan Ling</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>saxagliptin</keyword>
  <keyword>endothelial progenitor cell</keyword>
  <keyword>flow-mediated dilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

